telehealth.helpFind my match

Home WikiTelehealth Concepts

Titration (dose escalation)

From WikiTelehealth, the telehealth.help reference · Last updated

Titration, or dose escalation, is the practice of starting a medicine at a low dose and raising it in steps until the maintenance dose is reached. GLP-1 medicines are titrated mainly to reduce stomach side effects such as nausea.

Titration (dose escalation)
TypeDosing method
Also calledDose escalation, up-titration
PurposeBetter tolerance of side effects
Used withSemaglutide, tirzepatide, liraglutide, orforglipron
Set byThe FDA-approved label and the prescriber

Purpose

GLP-1 receptor agonists slow stomach emptying and act on appetite in the brain. Starting at a full dose would cause nausea, vomiting or diarrhea in many people. Titration gives the body time to adjust. The starting doses are usually not meant to be the doses that produce the main effect; they are steps on the way.

How labels describe it

Each FDA label lists a starting dose, the steps and the maintenance dose. For weekly injections such as Wegovy (semaglutide) and Zepbound (tirzepatide), the labels raise the dose at intervals of 4 weeks or more, so reaching the maintenance dose takes several months. Daily tablets such as Foundayo use steps of about 30 days. The FDA noted when it approved Zepbound that the dose is raised over 4 to 20 weeks to reach the target dose.

Labels also describe what a prescriber may do if a step is not tolerated, such as waiting longer before the next increase. Some labels advise restarting at a lower step after several missed doses. Decisions about the dose are made by the prescriber.

Maintenance doses differ by product. The Wegovy injection label lists 1.7 mg or 2.4 mg once weekly as maintenance doses, with 7.2 mg as a later option for some adults. The FDA described Zepbound target doses of 5 mg, 10 mg or 15 mg once weekly. The Foundayo label starts at 0.8 mg for at least 30 days before the first increase.

Titration in trials

In clinical trials such as STEP 1 and SURMOUNT-1, participants went through the same kind of escalation before reaching the dose being studied. Weight-loss results are usually reported at the end of the trial, after many months at the maintenance dose. Early weeks on a low step often show less change.

Stomach side effects in these trials were most common in the weeks after a dose increase and tended to ease over time. This pattern is the main reason the labels use small steps.

Titration and online care

People who get GLP-1 medicines through telehealth usually have check-ins with the prescriber before each step up. Some programs adjust the pace based on side effects. The way online programs handle follow-up is compared on our GLP-1 online page. See also microdosing, a different practice that uses doses below the labeled steps.

Compare online GLP-1 programs

See also

References

  1. Wegovy prescribing information, DailyMed (revised 2026). dailymed.nlm.nih.gov
  2. Zepbound prescribing information, DailyMed (revised 2026). dailymed.nlm.nih.gov
  3. Foundayo prescribing information, DailyMed (2026). dailymed.nlm.nih.gov
  4. FDA approves new medication for chronic weight management (FDA, November 8, 2023). fda.gov

Last updated . Category: Concepts. Browse all 38 WikiTelehealth entries.